Zimmer Biomet Holdings, Inc. (NYSE:ZBH) issued its earnings results on Wednesday. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02), Bloomberg Earnings reports. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same period in the previous year, the company earned $1.79 earnings per share. Zimmer Biomet Holdings’s revenue for the quarter was down .8% compared to the same quarter last year. Zimmer Biomet Holdings updated its Q4 guidance to $2.08-$2.14 EPS and its FY17 guidance to $8.01-$8.07 EPS.
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Friday, September 22nd were issued a dividend of $0.24 per share. The ex-dividend date was Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a yield of Infinity. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 30.19%.
A number of equities analysts have recently weighed in on ZBH shares. BMO Capital Markets reaffirmed a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Wells Fargo & Company reaffirmed a “market weight” rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Morgan Stanley upped their price target on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, July 17th. Stifel Nicolaus reiterated a “hold” rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $135.00.
COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Releases Earnings Results, Misses Estimates By $0.02 EPS” was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2017/11/03/zimmer-biomet-holdings-inc-zbh-releases-earnings-results-misses-estimates-by-0-02-eps.html.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.